tailieunhanh - Báo cáo y học: "First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài:First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]. | Available online http content 8 2 R35 Research article First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee a randomized double-blind placebo-controlled comparison with celecoxib NCT00267215 Ralf H Wittenberg1 Ernest Schell2 Gerhard Krehan3 Roland Maeumbaed4 Hans Runge5 Peter Schluter6 Taiwo OA Fashola7 Helen J Thurston7 Klaus J Burger8 and Ulrich Trechsel7 1Orthopaedische Abteilung St Elisabeth Hospital Herten Germany 2Promedica GmbH Nurnberg Germany 3Offenbachweg 1 Graben-Neudorf Germany 4Praxis Dr Maeumbaed Hochstadt Germany 5Praxis Dr Runge Erlangen Germany 6Praxis Dr Schluter Hemsbach Germany 7Novartis Pharma AG Basel Switzerland 8Novartis Pharma GmbH Nurnberg Germany Corresponding author Ralf H Wittenberg orthorw@ Received 29 Jun 2004 Revisions requested 21 Sep 2004 Revisions received 13 Sep 2005 Accepted 23 Dec 2005 Published 16 Jan 2006 Arthritis Research Therapy 2006 8 R35 doi ar1 854 This article is online at http content 8 2 R35 2006 Wittenberg et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib Prexige versus placebo and celecoxib in patients with knee osteoarthritis. This seven day double-blind placebo and active comparator controlled parallel group study included 364 patients aged 50 years with moderate-to-severe symptomatic knee osteoarthritis. Patients received lumiracoxib 400 mg day four times the recommended chronic dose in osteoarthritis n 144 placebo n 75 or .

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
165    86    0    29-04-2024
44    100    0    29-04-2024
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.